Our mission: to bring a new generation of best-in-class gene therapies to patients suffering from neuromuscular diseases.
Evry, France
Joined October 2021
- Tweets36
- Following234
- Followers225
- Likes30
In honor of LGMD Awareness day, @atamyoTX announces key milestones in our #genetherapy for #LGMD. Read the full release: bit.ly/3Y2NZy3
@AtamyoTX is proud to announce this new partnership with The Dion Foundation to expand our first-in-human trial of ATA-200 #genetherapy to treat LGMD2C/R5 in the US. Read full press release here: bit.ly/3ZdZmEi #LGMD #MuscularDystrophy
Atamyo Therapeutics Obtains US FDA Fast Track Designation for ATA-100, a Gene Therapy in Phase 1/2 Clinical Trials for Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) atamyo.com/press-releases/at…
Atamyo Therapeutics retweeted
ICYMI:
The trial, which will take the form of a dose escalation study, is expected to enroll 6 participants in total.
#MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy @AtamyoTX
Read more:
cgtlive.com/view/atamyo-limb…
@atamyotx #LGMD programs featured in scientific presentations at #Myology2024. #genetherapy Details: bit.ly/49TzQFX . .
@AtamyoTX approved to initiate #clinicaltrial of ATA-200 in France and Italy. ATA-200 single-injection #genetherapy aimed to treat LGMD2C/R5 caused by mutations in the g-sarcoglycan gene. Ph1b study to evaluate safety and efficacy in children. bit.ly/3U440SB
#LGMD
Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 - businesswire.com/news/home/2…
Atamyo Therapeutics' CEO, Stephane Degove, will present Atamyo's progress at the forthcoming 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) in Zurich, on 28th February at 12:20 (Room Berne). Looking forward to meeting the Finance and Biotech/Pharma community.
First results of ATA-100 in Ph1b/2b clinical trial presented at #ESGCT23. ATA-100 is one-time #genetherapy for FKRP LGMD2I/R9. Also announced, DSMB authorized enrollment of 2nd dose cohort of the ATA-001 #clinicaltrials #LGMB #musculardystrophy
bit.ly/46OqhYc
@AtamyoTX stands by the #LGMD Community and reiterates its full commitment to develop treatments for LGMD and to better describe how this disease affects patients' lives. #LgmdAwareness #genetherapy
@AtamyTX and our #LGMD #genetherapy programs will be represented at October conferences across the US and in EU. See you there. #musculardystrophy
Details: bit.ly/468yBSx
Another key milestone reached for @AtamyoTX and for the #LGMD community, this time with a potential one-time treatment for the devastating LGMD2C/R5 disease. #genetherapy #musculardystrophy
@AtamyoTX announces @US_FDA cleared its IND for ATA-100 to proceed in a Phase 1b/2b #ClinicalTrials. ATA-100 is one-time #genetherapy for treatment of fukutin-related protein (FKRB) #LGMD Type 2I/R9. #musculardystrophy Details: bit.ly/48fON5U
@atamyotx announces appointment of Roger Hajjar, MD, Dir of the Gene and Cell Therapy Institute of @MassGenBrigham to it’s Board of Directors. Dr. Hajjar is a gene therapy pioneer and internationally recognized scientist. atamyotx.com #genetherapy #LGMD
#CGMed23 tomorrow at 4PM @AtamyoTX company update by CEO Stephane Degove. Hope to see you there. #GeneTherapy
Atamyo Therapeutics retweeted
@atamyotx will be at #MeetingontheMed in Barcelona to present a company overview. Atamyo’s most advanced programs address different forms of #LGMD, with a clinical-stage program targeting LGMD-R9.#CellandGene #CGMed23
@atamyotx will be at #MeetingontheMed in Barcelona to present a company overview. Atamyo’s most advanced programs address different forms of #LGMD, with a clinical-stage program targeting LGMD-R9.#CellandGene #CGMed23
It's #LGMD Awareness Day!
@AtamyoTX
Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by
@AtamyoTX. Proud to develop treatments for this devastating disease
Atamyo Therapeutics retweeted
It's #LGMD Awareness Day! @GenethonFr , Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by @AtamyoTX , a Genethon spin-off
👉bit.ly/3Cmjk3W
Atamyo Therapeutics retweeted
Oggi 30 settembre l'ottava GIORNATA MONDIALE dedicata alla distrofia muscolare dei cingoli - patologie neuromuscolari LGMD. GFB ONLUS è impegnata nell'azione di sensibilizzazione su questa malattia rara Seguiteci sui profili social per rimanere aggiornati sulla GIORNATA. – at Sondrio, Lombardia
